Megestrol Acetate for Endometrial Cancer

Phase-Based Progress Estimates
Endometrial Cancer+1 MoreMegestrol Acetate - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether a combination of two drugs, megestrol acetate and metformin, is more effective than megestrol acetate alone in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.

Eligible Conditions
  • Endometrial Cancer
  • Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 42 days post surgery

Ki-67 expression
Day 42
Changes in protein expression
Day 42
Percentage of Ki-67 positive cells

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Arm I (megestrol acetate)
1 of 2
Arm II (megestrol acetate, metformin hydrochloride)
1 of 2

Active Control

Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: Megestrol Acetate · No Placebo Group · Phase 2

Arm II (megestrol acetate, metformin hydrochloride)Experimental Group · 3 Interventions: Megestrol Acetate, Questionnaire Administration, Extended Release Metformin Hydrochloride · Intervention Types: Drug, Other, Drug
Arm I (megestrol acetate)ActiveComparator Group · 3 Interventions: Biopsy, Megestrol Acetate, Questionnaire Administration · Intervention Types: Procedure, Drug, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Megestrol acetate
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 42 days post surgery

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,098 Previous Clinical Trials
41,145,727 Total Patients Enrolled
70 Trials studying Endometrial Cancer
70,467 Patients Enrolled for Endometrial Cancer
Emma BarberPrincipal InvestigatorNorthwestern University

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients must have completed treatment and achieved a cured status for hepatitis C virus infection, or be currently on treatment with an undetectable HCV viral load.
You are eligible for the study if you have been diagnosed with EIN on an endometrial biopsy or dilation and curettage specimen within three months prior to enrollment, including terms such as complex atypical hyperplasia and atypical hyperplasia.
You must be 18 or older to participate in this study, as EIN is largely experienced by adults and there is insufficient data available about the effects of megestrol acetate on participants younger than 18.
Your ECOG performance status is less than or equal to 2 and your Karnofsky score is greater than or equal to 60%.
Your total bilirubin levels are at or below the upper limit of what is considered normal for your healthcare provider.
Your AST/ALT ratio is equal to or less than 3.0 times the institutional upper limit of normal.
Your creatinine level is at or below the recommended maximum for your institution.
Individuals who are HIV-positive and have undetectable viral load after receiving anti-retroviral therapy for at least 6 months are qualified to participate in this trial.
Patients with chronic HBV must have an undetectable viral load, if suppressive therapy is prescribed.
Individuals receiving long-term antiviral medication for HSV infection are eligible.